ABLIM1は,PI3K/AKTシグナル伝達経路のDCC媒介活性化により,骨肉腫の増殖,移動および侵入を促進する
1Department of Orthopedic Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Cellular signalling
|August 22, 2025
まとめ
アクチン結合型LIMタンパク質1 (ABLIM1) は,骨肉腫の成長と広がりを促進する. ABLIM1を阻害することで,腫瘍の発達が抑制され,骨肉腫治療の潜在的治療標的として示唆された.
科学分野:
- 腫瘍学
- 分子生物学
- 生物化学
背景:
- アクチン結合型LIMタンパク質1 (ABLIM1) は,E3ユビキチンリガゼで,骨肉腫における役割は不明である.
- ABLIM1の機能を理解することは,新しい骨肉腫治療法の開発に不可欠です.
研究 の 目的:
- 骨肉腫細胞の行動におけるABLIM1の役割を調査する.
- 骨髄腫におけるABLIM1の機能の基礎となる分子メカニズムを解明する.
- ABLIM1を予後指標と治療目標として評価する.
主な方法:
- 骨肉肉腫におけるABLIM1発現のバイオ情報分析と実験的検証
- 細胞増殖,移動,侵入を評価するために,in vitro検査 (CCK-8,EDU,傷の治癒,Transwell) を行う.
- ウェスタン・ブロッティング,代謝プロファイリング,そして下流経路と機能を調査するインビオ異種移植モデル.
主要な成果:
- 骨肉肉腫ではABLIM1の調節不全が観察されました.
- ABLIM1を静止すると,骨肉腫細胞の増殖,移動,侵入が抑制された.
- ABLIM1の過剰発現は,これらの悪性行動を増強した.
- in vivo試験では,ABLIM1の抑制が腫瘍の成長を阻害することを確認した.
結論:
- ABLIM1は,細胞の成長,移動,侵入を促すことで,骨肉腫における腫瘍遺伝子として作用する.
- ABLIM1はDCC/PI3K/AKT/mTORシグナル伝達経路を調節する.
- ABLIM1はオステオサルコマの潜在的独立した予後因子であり,治療標的である.
関連する概念動画
01:22PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
01:35Cancer Cell Migration through Invadopodia
2.4K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.4K
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
01:20The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K